31444 results about "Phosphoric acid" patented technology

Nucleotide triphosphate probes containing a molecular and / or atomic tag on a a γ and / or β phosphate group and / or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed.

Nucleotides and nucleotide analogs are used in various sequencing by incorporation / sequencing by synthesis methods. Nucleotide analogs comprising 3′-blocking groups are used to provide reversible chain-termination for sequencing by synthesis. Typical blocking groups include phosphate groups and carbamate groups. Fluorescent nucleotides are used to perform sequencing by synthesis with detection by incorporation of the fluorescently labeled nucleotide, optionally followed by photobleaching and intercalating dyes are used to detect addition of a non-labeled nucleotide in sequencing by synthesis with detection by intercalation. Microfluidic devices, including particle arrays, are used in the sequencing methods.

A method of characterizing a nucleic acid sample is provided that includes the steps of: (a) conducting a DNA polymerase reaction that includes the reaction of a template, a non-hydrolyzable primer, at least one terminal phosphate-labeled nucleotide, DNA polymerase, and an enzyme having 3′→5′ exonuclease activity which reaction results in the production of labeled polyphosphate; (b) permitting the labeled polyphosphate to react with a phosphatase to produce a detectable species characteristic of the sample; (c) detecting the detectable species; and (d) characterizing the nucleic acid sample based on the detection.

A heat-sensitive negative-working lithographic printing plate precursor includes on a grained and anodized aluminum support a coating including hydrophobic thermoplastic polymer particles, a hydrophilic binder, and an organic compound, wherein the organic compound includes at least one phosphonic acid group or at least one phosphoric acid group or a salt thereof.

Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2′-O or 3′-O-alkyl group, preferably a methyl group, producing analogs called BH3-ARCAs or Se-ARCAs. ARCAs may be modified with α-, β-, or γ-boranophosphate or phosphoroselenoate groups.

One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one aralkyl ligand. In certain embodiments, an aralkyl ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, an aralkyl ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage. In a preferred embodiment, the aralkyl ligand is naproxen or ibuprofen. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one aralkyl ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage. In a preferred embodiment, the aralkyl ligand is naproxen or ibuprofen. The aralkyl ligand improves the pharmacokinetic properties of the oligonucleotide.

A system is provided for the storage, preparation and administration of calcium phosphate cements. The subject invention provides a storage means for storing a two component calcium phosphate cement having a liquid component and a dry component. Also provided is a preparation means for combining the two components of the cement while present in the storage means. The subject invention further provides a means for administering the prepared cement to a physiological site. The subject devices and methods find use in a variety of applications where the introduction of a flowable material capable of setting to a solid calcium phosphate mineral to a physiological site is desired, including dental and orthopedic applications.

This invention provides an amorphous oxide semiconductor thin film, which is insoluble in a phosphoric acid-based etching solution and is soluble in an oxalic acid-based etching solution by optimizing the amounts of indium, tin, and zinc, a method of producing the amorphous oxide semiconductor thin film, etc. An image display device (1) comprises a glass substrate (10), a liquid crystal (40) as a light control element, a bottom gate-type thin film transistor (1) for driving the liquid crystal (40), a pixel electrode (30), and an opposing electrode (50). The amorphous oxide semiconductor thin film (2) in the bottom gate-type thin film transistor (1) has a carrier density of less than 10+18 cm−3, is insoluble in a phosphoric acid-based etching liquid, and is soluble in an oxalic acid-based etching liquid.

Sealant compositions comprising an alkali swellable latex and a pH increasing material and methods of using the same to service a wellbore are provided. In one embodiment, the sealant composition can be used in a wellbore and includes an alkali swellable latex and a pH increasing material. The sealant composition can have a pH of from about 7 to about 14. In other embodiments, the pH increasing material includes a base-producing material. The base-producing material can include alkali and alkali earth metal carbonates, alkali and alkali earth metal bicarbonates, alkali and alkali earth metal hydroxides, alkali and alkali earth metal oxides, alkali and alkali earth metal phosphates, alkali and alkali earth metal hydrogen phosphates, alkali and alkaline earth metal sulphides, alkali and alkaline earth metal salts of silicates, alkali and alkaline earth metal salts of aluminates, water soluble or water dispersible organic amines, polymeric amine, amino alcohols, or combinations thereof.

A method of characterizing an analyte sample is provided that includes the steps of: (a) anchoring the analyte to a nucleic acid template of known sequence; (b) conducting a DNA polymerase reaction that includes the reaction of a template, a non-hydrolyzable primer, at least one terminal phosphate-labeled nucleotide, DNA polymerase, and an enzyme having 3'->5' exonuclease activity which reaction results in the production of labeled polyphosphate; (c) permitting the labeled polyphosphate to react with a phosphatase to produce a detectable species characteristic of the sample; (d) detecting the detectable species. The method may include the step of characterizing the nucleic acid sample based on the detection. Also provided are methods of analyzing multiple analytes in a sample, and kits for characterizing analyte samples.

The invention provides a method of distinguishing small RNA from mRNA by contacting a biological isolate with a phosphate reactive reagent having a label moiety under conditions wherein the label moiety is preferentially added to the 5′ phosphate of small RNA over the 5′ cap structure of mRNA and distinguishing the small RNA from the mRNA according to the presence of the label. The invention further provides a method of identifying a plurality of different small RNAs by adding a unique extension sequences to different small RNA sequences and identifying the extended small RNA sequences. Furthermore, the invention provides diagnostic methods for determining presence of a disease or condition such as cancer. Also provided are prognostic methods for determining progression of a disease or condition or for monitoring effectiveness of a treatment for a disease or condition

The present invention provides a composition comprising the product prepared by hearing together: (a) a dispersant; and (b) a 1,3-dicarboxylic acid or 1,4-dicarboxylic acid of an aromatic compound, or a reactive equivalent thereof; and at least one of: (c) 2,5-dimercapto-1,3,4-thiadiazole or a hydrocarbyl-substituted 2,5-dimercapto-1,3,4-thiadiazole, or an oligomer thereof; (d) a borating agent; and (e) a phosphorus acid compound, or a reactive equivalent thereof, said heating being sufficient to provide a reaction product of (a), (b), and (c), (d), or (e), which is soluble in an oil of lubricating viscosity. The invention further provides a use for the composition.

Zirconium phosphate particles are synthesized by providing a solution of zirconium oxychloride in an aqueous solvent, adding at least one low molecular weight, oxygen containing, monofunctional, organic additive to the solution, and combining this solution with heated phosphoric acid or a phosphoric acid salt to obtain zirconium phosphate particles by sol gel precipitation.

The invention discloses a precipitation method for preparing nanometer level iron phosphate lithium coated with carbon. The method comprises the following steps: firstly, weighing iron salt, deionized water and a compound of metallic elements; after the stirring and the mixing are performed, adding a phosphorous compound and citric acid diluted with water to the mixture; after the stirring is performed again, adding a precipitation agent to the mixture and controlling to the neutrality; stirring to react in a container, and after the static placement, respectively adding the deionized water, a carbon source and lithium salt to mix uniformly after the precipitate is filtered and washed; stirring again to react, and drying the water at 30 to 160 DEG C and warming up at the heating rate under the protection of non-oxidized gas after a product is crashed; baking at a constant temperature of 450 to 850 DEG C, cooling down to a room temperature at a cooling rate or with a stove, and finally obtaining the nanometer level ferric phosphate lithium coated with the carbon after crashing is performed. The precipitation method has the advantage that the raw material cost and the processing cost are low because bivalent iron is taken as the raw material. The iron phosphate lithium prepared by using the process has the characteristics of good physical processing performance and good electrochemistry performance, and is suitable for industrialized production.

A transparent conductive film comprising a polymer film and a transparent conductive layer provided thereon, especially a transparent conductive film improved in durability and mechanical and electrical properties, a process for the preparation thereof, and a touch panel provided with the transparent conductive film, as well as transparent conductive plate and the process for the preparation thereof. The transparent conductive film comprising a polymer film, an undercoat layer and a transparent conductive layer which are superposed in this order, and the undercoat layer contains a compound having at least one selected from an amino group and a phosphoric acid group.

Panchromatic photosensitizers having a Formula of ML1L2X were synthesized, wherein M comprises ruthenium atom; X is a monodentate anion; L1 is heterocyclic bidentate ligand having one of formulae listed below:wherein G2 has one of formulae listed below:and L2 is a tridentate ligand having a formula listed below:The substituents R1, R2, R3, R4, R5, R6, R7 of L1 and L2 are the same or different, and represent alkyl, alkoxy, alkylthio, alkylamino, halogenated alkyl, phenyl or substituted phenyl group, carboxylic acid or counter anion thereof, sulfonic acid or counter anion thereof, phosphoric acid or counter anion thereof, amino-group, halogens, or hydrogen. The above-mentioned photosensitizers are suitable to use as sensitizers for fabrication of high efficiency dye-sensitized solar cell.

One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.

The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and / or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Processes are disclosed that use 3′-reversibly terminated nucleoside triphosphates to analyze DNA for purposes other than sequencing using cyclic reversible termination. These processes are based on the unexpected ability of terminal transferase to accept these triphosphates as substrates, the unexpected ability of polymerases to add reversibly and irreversibly terminated triphosphates in competition with each other, the development of cleavage conditions to remove the terminating group rapidly, in high yield, and without substantial damage to the terminated oligonucleotide product, and the ability of reversibly terminated primer extension products to capture groups. The presently preferred embodiments of the disclosed processes use a triphosphate having its 3′-OH group blocked as a 3′-ONH2 group, which can be removed in buffered NaNO2 and use variants of Taq DNA polymerase, including one that has a replacement (L616A).

The present invention relates to a process for producing a water-absorbent polysaccharide including the process steps of bringing into contact an uncrosslinked polysaccharide with a polyphosphate or a polyphosphoric acid as crosslinking agent in the presence of water to form a polysaccharide gel and crosslinking the polysaccharide gel. The invention further relates to a water-absorbent polysaccharide obtainable by this process, a water-absorbent polysaccharide, a composite, a process for producing a composite, a composite produced by this process, the use of the water-absorbent polysaccharides or of the composites as well as the use of polyphosphates.

Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided.

The present invention describes terminal phosphate blocked nucleoside polyphosphates that are stable at high temperature and their use in nucleic acid amplification and analysis. Current invention further describes charge modified terminal phosphate blocked nucleoside polyphosphates for improved incorporation and direct loading of nucleic acid sequencing reactions onto separating media.

Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose 6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.

Disclosed are phosphor compositions having the formulas Ca1−a−bCeaEubAl1+aSi1−aN3, where 0<a≦0.2, 0≦b≦0.2; Ca1−c−dCecEudAl1−c(Mg,Zn)cSiN3, where 0<c≦0.2, 0≦d≦0.2; Ca1−2e−fCee(Li,Na)eEufAlSiN3, where 0≦e≦0.2, 0≦f≦0.2, g+h>0; and Ca1−g−h−iCeg(Li,Na)hEuiAl1+g−hSi1−g+hN3 where 0≦g≦0.2, 0<h≦0.4, 0≦i≦0.2,g+i>0. When combined with radiation from a blue or UV light source, these phosphors can provide light sources with good color quality having high CRI over a large color temperature range. Also disclosed are blends of the above phosphors and additional phosphors.

The present invention provides methods for generating CMP-sialic acid in a non-human host which lacks endogenous CMP-Sialic by providing the host with enzymes involved in CMP-sialic acid synthesis from a bacterial, mammalian or hybrid CMP-sialic acid biosynthetic pathway. Novel fungal hosts expressing a CMP-sialic acid biosynthetic pathway for the production of sialylated glycoproteins are also provided.

The invention discloses a method for preparing magnetic biological carbon adsorbing material and the usage thereof. The method comprises the steps: 1) drying and crushing waste biomass, and sieving by20-100 meshes; 2) putting the sieved biomass into 0.1-0.5mol / L of iron salt solution with the weight percent of the biomass being 1-10% of the total quantity; under stirring, dripping 3-6mol / L of NaOH solution until the pH value of the solution is 9-10; 3) filtering, drying and compacting the solid precipitate, and then limiting oxygen carbonizing for 1-5h at the temperature of 100-700 DEG C, thus obtaining the magnetic biological carbon adsorbing material; 4) putting the magnetic biological carbon adsorbing material into waste water, and simultaneously removing organic pollutant and phosphate radical in the waste water. The method realizes synchronization of preparation of the adsorbing material and the process of magnetization, and is simple in preparation process, rich in the source ofthe biomass material and low in cost; furthermore, the prepared magnetic adsorbent is covered by biological carbon or embedded with magnetic nano Fe3O4 granules, has special structure and stable existence, can effectively remove the organic pollutant and phosphate in the waste water, and is easy for magnetic separation.

A bone-repair composite includes a core and a sheath. The core is a first primary unit including a combination of a first set of yarns coated with a calcium phosphate mineral layer. The first set of yarns being made from a first group of one ore more polymers. The sheath is a second primary unit a combination of a second set of yarns or one or more polymer coatings. The second set of yarns being made from a second group of one or more polymers, wherein the composite is made by covering the core with the sheath, and the composite is compression molded to allow the sheath to bond to the core. The bone-repair composite has a bending modulus comparable to that of a mammalian bone, such that the ratio of the core to the sheath is provided to maximize the mechanical strength of the bone-repair composite to mimic the mammalian bone.

An acidic aqueous hydrogen peroxid solution is provided, with improved disinfectant activity. Concentrated solutions preferably contain up to about 8% and as-used concentrations contain about 0.5% peroxide. The solution also contains from 0.1 to 5.0% of at least one acid compound, e.g. phosphoric and / or a phosphonate with from 1 to 5 phosphonic acid groups, and from 0.02 to 5% of at least one anionic surfactant. The surfactant is selected from C8 to C16-alkyl aryl sulphonic acids, sulphonated C12 to C22 carboxylic acids, C8 to C22-alkyl diphenyl oxide sulphonic acids, naphthalene sulphonic acids, C8 to C22 alkyl sulphonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulphates, and mixtures thereof. Most preferably the solution has an emulsifier, e.g. a salt of an alkylated diphenyl oxide. The solution may also contain corrosion inhibitors and / or lower alcohols.